BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AK139 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AK139\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07436221-1281@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20261227
DTEND;VALUE=DATE:20261228
SUMMARY:AK139: Phase 2 readout est. (NCT07436221)
DESCRIPTION:AK139\, phase 2\, Asthma.\nStudy: A Study to Evaluate the Effic
 acy and Safety of AK139 in Participants With Asthma\nEstimated primary com
 pletion: 27 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/ak139#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07436221
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755371-1281@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:AK139: Phase 2 readout est. (NCT07755371)
DESCRIPTION:AK139\, phase 2.\nStudy: A Study to Evaluate the Efficacy and S
 afety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Poly
 ps\nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ak139#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07755371
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07883213-1281@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:AK139: Phase 2 readout est. (NCT07883213)
DESCRIPTION:AK139\, phase 2\, Prurigo Nodularis.\nStudy: A Study to Evaluat
 e the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.\nEs
 timated primary completion: August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/ak139#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07883213
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502222-1281@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:AK139: Phase 2 readout est. (NCT07502222)
DESCRIPTION:AK139\, phase 2\, Atopic Dermatitis.\nStudy: A Study to Evaluat
 e the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Ato
 pic Dermatitis\nEstimated primary completion: November 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ak139#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07502222
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07875426-1281@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20290108
DTEND;VALUE=DATE:20290109
SUMMARY:AK139: Phase 2 readout est. (NCT07875426)
DESCRIPTION:AK139\, phase 2\, Chronic Spontaneous Urticaria.\nStudy: A Tria
 l to Evaluate the Efficacy and Safety of AK139 in Participants With Chroni
 c Spontaneous Urticaria\nEstimated primary completion: 8 January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ak139#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07875426
URL:https://assetmemo.bio/drug/ak139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
